Please provide your email address to receive an email when new articles are posted on . Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis.

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

Johnson & Johnson is chasing giants in immunology with a plaque psoriasis nod from the FDA––and fast-growing sales––to show for it so far. Not content with that, though, Tremfya is pushing toward ...

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA ®, the only dual-acting IL-23 inhibitor HORSHAM, Pa., July 29, ...

Johnson & Johnson is battling giants in the immunology field with its IL-23 inhibitor Tremfya. With other next-gen drugs already crowding the market, J&J now has the FDA's nod to take Tremfya into ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

In addition, results showed 56 percent of TREMFYA q4w patients and 55 percent of TREMFYA q8w patients achieved at least 50 percent improvement in ACR score (utilizing NRI). 2 Among patients who had ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has approved guselkumab, an interleukin-23 ...

Additionally, for patients in the study's placebo group, who switched to TREMFYA ® at Week 24, the rate of radiographic progression from baseline to Week 24 (0.96) was reduced by 57% (to 0.41) from ...